Trillium Therapeutics Inc. (NASDAQ:TRIL, TSX:TR)
Trillium Therapeutics Inc.
2488 Dunwin Drive
Canada L5L 1J9
Tel: +1 416.595.0627
Trillium Therapeutics is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. We have two premier pre-clinical programs, SIRPαFc and a CD200 monoclonal antibody, which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system.
SEC filings: http://www.nasdaq.com/symbol/tril/sec-filings
Canadian Insider: https://www.canadianinsider.com/company?menu_tickersearch=tr
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Last update 6/17/2016
Rules of the board according to IHUB: